In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
All of 6 heat-treated prothrombin complex concentrates (PCC) tested contained adequate levels of factor IX but factor VII content was low. Levels of factors II, X, protein C and protein S were variable and antigen levels were always greater than those of functional activities. On crossed-immunoelectrophoresis factor IX showed variable anodal shift in all concentrates tested and in some activated factor IX was demonstrated by immunoblotting technique. These findings suggested some activation and/or denaturation during production and/or heating. Modest amount of factor VIII clotting activity by solid-phase amidolytic method and of factor VIII antigen was demonstrated in some concentrates but none contained more than a trace factor VIII inhibitor bypassing activity. The results suggested that heat-treated PCC should provide safe therapeutic products for hemophilia B.
D001779:Blood Coagulation Factors / Q000032:analysis*; D004591:Electrophoresis, Polyacrylamide Gel; D005164:Factor IX / Q000032:analysis; D005169:Factor VIII / Q000032:analysis / Q000037:antagonists & inhibitors; D006023:Glycoproteins / Q000032:analysis; D006358:Hot Temperature; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional; D011486:Protein C / Q000032:analysis; D017293:Protein S
D001779:Blood Coagulation Factors; D006023:Glycoproteins; D011486:Protein C; D017293:Protein S; C025667:prothrombin complex concentrates; D005169:Factor VIII; D005164:Factor IX